Chronic Obstructive Pulmonary Disease (COPD)

Overview

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

Global Burden: COPD affects approximately 384 million people globally and caused 3.2 million deaths in 2019, making it the third leading cause of death worldwide.

Causes & Pathophysiology

Primary Causes:

Tobacco smoking: Accounts for 85-90% of cases
Environmental exposures: Biomass fuel, occupational dusts/chemicals
Genetic factors: Alpha-1 antitrypsin deficiency (rare)
Air pollution: Both indoor and outdoor
Recurrent respiratory infections in childhood

Pathophysiology:

Chronic inflammation → small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema) → airflow limitation that is not fully reversible → gas exchange abnormalities → systemic manifestations.

COPD Phenotypes:

Phenotype	Characteristics	Dominant Pathology
Chronic Bronchitis	Productive cough, frequent infections	Airway inflammation, mucus hypersecretion
Emphysema	Dyspnea, weight loss, barrel chest	Alveolar destruction, air trapping
Frequent Exacerbator	≥2 exacerbations/year	Mixed airway and systemic inflammation
Asthma-COPD Overlap	Features of both asthma and COPD	Mixed eosinophilic and neutrophilic inflammation

Symptoms & Presentation

Core Symptoms:

Dyspnea: Progressive, persistent, worse with exercise
Chronic cough: May be productive or dry
Sputum production: Chronic, may be mucoid or purulent
Wheezing: Not always present
Chest tightness

GOLD Classification of Airflow Limitation:

GOLD Stage	FEV1 (% predicted)	Characteristics
GOLD 1 (Mild)	≥80%	May be unaware of lung function impairment
GOLD 2 (Moderate)	50-79%	Shortness of breath on exertion
GOLD 3 (Severe)	30-49%	Worsening symptoms, reduced quality of life
GOLD 4 (Very Severe)	<30%	Quality of life considerably impaired, exacerbations

Physical Examination Findings:

Increased anteroposterior chest diameter (barrel chest)
Pursed-lip breathing
Use of accessory muscles
Distant heart sounds
Hyperresonance on percussion
Wheezing or diminished breath sounds
Digital clubbing (if associated conditions)
Peripheral edema (in cor pulmonale)

Risk Factors

Major Risk Factors:

Smoking: Current or former smoking (pack-years)
Age: Usually >40 years at diagnosis
Occupational exposures: Coal dust, silica, cadmium
Indoor air pollution: Biomass fuel for cooking/heating
Outdoor air pollution
Childhood respiratory infections
Asthma or airway hyperresponsiveness
Genetic factors: Alpha-1 antitrypsin deficiency
Low socioeconomic status

Factors for Disease Progression:

Continued smoking
Severe airflow limitation
Frequent exacerbations
Older age
Presence of emphysema on CT
Comorbidities (cardiovascular disease, osteoporosis)

Diagnosis & Investigations

Diagnostic Criteria:

Post-bronchodilator FEV1/FVC <0.70 confirms persistent airflow limitation in patients with appropriate symptoms and risk factors.

Key Investigations:

Investigation	Purpose	Findings in COPD
Spirometry	Confirm diagnosis, assess severity	FEV1/FVC <0.70, bronchodilator response <12%
Chest X-ray	Exclude other diagnoses	Hyperinflation, flattened diaphragms, bullae
CT Thorax	Detailed assessment	Emphysema distribution, comorbidities
Alpha-1 Antitrypsin	Screen for deficiency	Low levels in genetic deficiency
Arterial Blood Gas	Assess gas exchange	Hypoxemia, hypercapnia in advanced disease
6-Minute Walk Test	Functional assessment	Reduced exercise capacity

Differential Diagnosis:

Asthma
Heart failure
Bronchiectasis
TB sequelae
Obliterative bronchiolitis
Diffuse panbronchiolitis

Management & Treatment

Non-Pharmacological Management:

Smoking cessation: Most important intervention
Pulmonary rehabilitation: Comprehensive program
Vaccinations: Influenza and pneumococcal
Oxygen therapy: For chronic hypoxemia
Nutritional support: Address malnutrition or obesity
Self-management education

Pharmacological Treatment (GOLD Guidelines):

GOLD Group	Characteristics	Recommended Treatment
Group A	Low risk, few symptoms	Bronchodilator (SABA or LABA)
Group B	Low risk, more symptoms	LABA or LAMA
Group C	High risk, few symptoms	LAMA
Group D	High risk, more symptoms	LAMA + LABA, consider ICS

Medication Classes:

Bronchodilators: Beta-agonists (SABA/LABA), Anticholinergics (SAMA/LAMA)
Inhaled Corticosteroids: For frequent exacerbators with elevated eosinophils
Phosphodiesterase-4 inhibitors: Roflumilast for severe COPD with chronic bronchitis
Methylxanthines: Theophylline (limited use due to side effects)
Antibiotics: For infectious exacerbations
Mucolytics: May reduce exacerbations in chronic bronchitis

Ayurvedic Treatment

Traditional Approaches:

Shodhana therapy: Detoxification through Panchakarma
Rasayana therapy: Rejuvenation and immune support
Pranayama: Breathing exercises for lung capacity

Herbal Formulations:

Sitopaladi Churna: With honey for cough and breathing
Talisadi Churna: Respiratory tonic and expectorant
Vasa Avaleha: For bronchial dilation and cough
Kanakasava: For respiratory strength and immunity
Chyawanprash: General rejuvenation and immunity

Ayurvedic Procedures:

Nasya: Nasal administration of medicated oils
Uro-vasti: Localized oil treatment on chest
Steam inhalation: With eucalyptus, camphor, or mint
Abhyanga: Therapeutic oil massage

Important: Ayurvedic treatments should complement conventional COPD management, not replace it. Never discontinue prescribed medications without medical supervision.

Diet, Lifestyle & Self-care

Nutritional Recommendations:

High-protein diet to prevent muscle wasting
Small, frequent meals to avoid abdominal distension
Foods rich in antioxidants (fruits, vegetables)
Omega-3 fatty acids (fish, flaxseeds) for anti-inflammatory effects
Adequate hydration to thin secretions
Limit salt intake if cor pulmonale present

Lifestyle Modifications:

Smoking cessation: Absolute necessity
Regular physical activity: As tolerated
Energy conservation techniques: Pacing activities
Breathing techniques: Pursed-lip breathing, diaphragmatic breathing
Avoid respiratory irritants: Pollution, strong fumes, dust
Infection prevention: Hand hygiene, avoid crowds during flu season

Self-management Strategies:

Recognize early signs of exacerbations
Proper inhaler technique
Action plan for exacerbations
Regular follow-up with healthcare team
Vaccination adherence
Stress management and psychological support

Prognosis

COPD is generally progressive, but the rate of progression varies. With comprehensive management, symptoms can be controlled and quality of life improved, though lung function decline may continue.

Factors Affecting Prognosis:

Smoking status (continued smoking worsens prognosis)
Severity of airflow limitation
Frequency and severity of exacerbations
Presence of comorbidities
Body mass index (both low and high BMI affect prognosis)
Exercise capacity
Adherence to treatment

BODE Index for Mortality Prediction:

Composite score based on:

Body mass index
Degree of airflow Obstruction (FEV1)
Dyspnea (MRC scale)
Exercise capacity (6-minute walk distance)

Potential Complications:

Acute exacerbations requiring hospitalization
Respiratory failure
Pneumonia
Pneumothorax
Chronic respiratory failure
Pulmonary hypertension and cor pulmonale
Secondary polycythemia
Depression and anxiety
Osteoporosis
Lung cancer

When to Seek Medical Care

Seek immediate medical attention for signs of acute exacerbation:

Worsening shortness of breath beyond normal daily variations
Increase in sputum volume
Change in sputum color (yellow or green)
Fever
Increased wheezing or chest tightness
Swelling in ankles or feet
Unusual fatigue or weakness
Confusion or drowsiness
Blue lips or fingernails
Rapid heartbeat

Prevention & Screening

Primary Prevention:

Smoking prevention and cessation: Most effective strategy
Reduction of occupational exposures: Proper ventilation, protective equipment
Improvement of indoor air quality: Clean cooking fuels, ventilation
Reduction of outdoor air pollution exposure
Childhood vaccination: Reduce respiratory infections

Secondary Prevention (Early Detection):

Spirometry screening for high-risk individuals (smokers >40 years)
Case finding in primary care for symptomatic patients
Workplace screening for high-risk occupations

Tertiary Prevention (Disease Management):

Comprehensive COPD management programs
Pulmonary rehabilitation
Exacerbation prevention strategies
Comorbidity management
Advanced care planning

Vaccination Recommendations:

Annual influenza vaccine
Pneumococcal vaccines (PCV13 and PPSV23)
COVID-19 vaccination
Tetanus-diphtheria-pertussis booster